1 299

Cited 25 times in

Cost of treatment for multidrug-resistant tuberculosis in South Korea

Authors
 Young Ae KANG  ;  Yong-Jun CHOI  ;  Young-Jae CHO  ;  Sang Min LEE  ;  Chul-Gyu YOO  ;  Young Whan KIM  ;  Sung Koo HAN  ;  Young-Soo SHIM  ;  Jae-Joon YIM 
Citation
 RESPIROLOGY, Vol.11(6) : 793-798, 2006 
Journal Title
 RESPIROLOGY 
ISSN
 1323-7799 
Issue Date
2006
MeSH
Adult ; Efficiency, Organizational/economics ; Female ; Health Care Costs/statistics & numerical data* ; Humans ; Korea/epidemiology ; Male ; Middle Aged ; Prevalence ; Time Factors ; Tuberculosis, Multidrug-Resistant/drug therapy* ; Tuberculosis, Multidrug-Resistant/economics* ; Tuberculosis, Multidrug-Resistant/epidemiology ; Tuberculosis, Pulmonary/drug therapy* ; Tuberculosis, Pulmonary/economics* ; Tuberculosis, Pulmonary/epidemiology
Keywords
cost ; multidrug‐resistant ; tuberculosis
Abstract
Objective and background: Costs associated with multidrug-resistant tuberculosis (MDR-TB) are higher than those associated with drug-susceptible TB because of the higher prices of second-line anti-TB drugs, the prolonged duration of treatment, greater productivity loss and higher mortality. The aim of this study was to estimate the cost of treatment for MDR-TB according to the treatment strategy and prognosis in South Korea. Methods: We estimated the direct (medical and non-medical) and indirect cost for the treatment of MDR-TB according to the treatment strategies and prognosis: in medically treated, surgically treated and deceased patients groups. The same analyses were undertaken for drug-susceptible TB for comparison. The patients with MDR-TB or drug-susceptible TB were randomly selected from the TB cohort of Seoul National University Hospital, Seoul, South Korea. Results: Direct costs per person were US$4000 (US$2527–4841) in the medically treated group, US$17 457 (US$10 133–26 418) in the surgically treated group and US$33 362 (US$25 386–40 338) in the deceased group. Total costs per person were US$15 856 (US$10 752–38 421), US$47 159 (US$20 587–77 622) and US$478 357 (US$257 377–777 778), respectively. For the patients with drug-susceptible TB, the total cost ranged from US$1680 to US$7637 (median US$2166). Conclusions: The cost for the treatment of MDR-TB is seven to 22 times that of managing the drug-susceptible TB in South Korea. Considering the high cost, transmissibility and considerable fatality of MDR-TB, there is a need to provide specific separate funding for multidrug-resistant tuberculosis.
Full Text
http://onlinelibrary.wiley.com/doi/10.1111/j.1440-1843.2006.00948.x/abstract
DOI
10.1111/j.1440-1843.2006.00948.x
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kang, Young Ae(강영애) ORCID logo https://orcid.org/0000-0002-7783-5271
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/111094
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links